专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015073988A1 COMPOSITIONS AND METHODS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST FACTOR VIII IN HEMOPHILIA A PATIENTS 审中-公开
标题翻译：抑制HEMOPHILIA A患者抑制因子VIII的抑制剂形成的组合物和方法
公开(公告)号：WO2015073988A1
公开(公告)日：2015-05-21
申请号：PCT/US2014/065994
申请日：2014-11-17
申请人： TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , OFFICE OF TECHNOLOGY LICENSING , HERZOG, Roland, W. , DANIELL, Henry
发明人： HERZOG, Roland, W. , DANIELL, Henry
IPC分类号： C12N5/02 , C12N5/00 , A01H9/00
CPC分类号： C07K14/28 , A61K36/00 , A61K38/36 , A61K38/37 , A61K38/45 , A61K38/47 , C07K14/755 , C07K2319/00 , C12N15/8214 , C12N15/8257 , C12Y204/00 , C12Y302/0102 , C12Y302/01022 , Y02A50/471
摘要： Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life -threatening anaphylactic reactions by formation of lgE. Using murine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures to intravenous coagulation factor protein.
摘要翻译：血友病或其他遗传性蛋白质缺乏症患者的蛋白质替代治疗通常由致病性抗体反应复杂化，包括中和治疗性蛋白质的抗体或易于通过形成lgE而潜在的生命危险的过敏反应。使用鼠血友病作为模型，我们制定了一种针对非侵入性反应的预防方案，不包括对患者细胞的免疫抑制或遗传操作。在植物细胞中生物封装的叶绿体中表达的凝血因子的口服递送在蛋白质替代疗法中有效阻断了抑制性抗体的形成。与对照相比，抑制剂滴度几乎不可检测，并且在治疗的受试者中高达100倍。此外，这种治疗消除了4至6次静脉内凝血因子蛋白暴露后发生的致命过敏反应。

2. 发明申请

WO2011057243A3 ADMINISTRATION OF PLANT EXPRESSED ORAL TOLERANCE AGENTS 审中-公开
标题翻译：工厂明示口服耐受药物的管理
公开(公告)号：WO2011057243A3
公开(公告)日：2011-11-17
申请号：PCT/US2010055978
申请日：2010-11-09
申请人： UNIV CENTRAL FLORIDA RES FOUND , UNIV FLORIDA , DANIELL HENRY , HERZOG ROLAND W
发明人： DANIELL HENRY , HERZOG ROLAND W
IPC分类号： A61K38/56 , A61K38/16 , A61K48/00 , A61P3/00 , A61P9/10 , A61P43/00
CPC分类号： A61K39/0008 , A61K38/4846 , C07K2319/55 , C12N9/644 , C12N15/8214 , C12N15/8257 , C12Y304/21022
摘要： Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine hemophilia B as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor IX (F. IX) expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated mice when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures to intravenous F. IX protein. While only 20-25% of control animals survived after 6-8 F. IX doses, 90-95% of tolerized mice survived 12 injections without signs of allergy or anaphylaxis. This high-responder strain of hemophilia B mice represents the first hemophilic animal model to study anaphylactic reactions. The plant material was effective over a range of oral antigen doses (equivalent to 5-80 µg recombinant F.IX/kg), and controlled inhibitor formation and anaphylaxis long-term, up to 7 months. Oral antigen administration caused a deviant immune response that suppressed formation of IgE and inhibitory antibodies. This cost-effective and efficient approach to oral delivery of protein antigens to the gut should be applicable to several genetic diseases that are prone to pathogenic antibody responses during treatment.
摘要翻译：对于患有血友病或其他遗传性蛋白质缺乏症的患者，蛋白质替代疗法通常由致病性抗体反应复杂化，包括中和治疗性蛋白质的抗体或易于形成IgE的潜在的威胁生命的过敏反应的抗体。使用鼠血友病B作为模型，我们制定了一种针对非侵入性反应的预防方案，不包括对患者细胞的免疫抑制或遗传操作。在植物细胞中生物封装的叶绿体中表达的凝血因子IX（F. IX）的口服递送在蛋白质替代疗法中有效阻断了抑制性抗体的形成。与对照相比，抑制剂滴度几乎不可检测，并且在治疗小鼠中高达100倍。此外，这种治疗消除了4至6次静脉注射F. IX蛋白暴露后发生的致命过敏反应。虽然只有20-25％的对照动物在6-8 F. IX剂量后存活，但90-95％的耐受性小鼠存活12次注射，没有过敏或过敏反应的迹象。这种高反应性血友病B型小鼠代表了研究过敏反应的第一个血液动力学模型。植物材料在一系列口服抗原剂量（相当于5-80μg重组FIX / kg）中有效，长期控制抑制剂形成和过敏反应，长达7个月。口服抗原给药导致抑制IgE和抑制性抗体形成的偏差免疫应答。将肠蛋白质抗原口服递送至肠道的成本效益高效的方法应适用于在治疗期间易发生致病性抗体反应的几种遗传性疾病。

3. 发明申请

WO2009049796A1 HEISSGASGEFÜHRTE KOMPONENTE EINER STRÖMUNGSMASCHINE 审中-公开
标题翻译：涡轮机的热气制导COMPONENT
公开(公告)号：WO2009049796A1
公开(公告)日：2009-04-23
申请号：PCT/EP2008/008452
申请日：2008-10-07
申请人： MAN TURBO AG , BEUKENBERG, Markus , CHANDRA, Sharad , CZECH, Norbert , HERZOG, Roland
发明人： BEUKENBERG, Markus , CHANDRA, Sharad , CZECH, Norbert , HERZOG, Roland
IPC分类号： C22C38/00 , C22C38/06 , C22C38/18 , C23C4/08 , C23C30/00 , F01D5/28
CPC分类号： C23C30/00 , B23K35/30 , B32B15/01 , B32B15/015 , B32B15/18 , B32B15/20 , C22C38/005 , C22C38/06 , C22C38/18 , C23C30/005 , F01D5/28 , F01D5/286 , F01D5/288 , Y10T428/12931 , Y10T428/12937 , Y10T428/12944 , Y10T428/12951 , Y10T428/12972 , Y10T428/12979
摘要： Offenbart ist eine heißgasgeführte Komponente für eine Strömungsmaschine, mit einer Nickel-Basisknetlegierung als Strukturwerkstoff und einer heißgasseitigen Auskleidung aus der Gruppe der Eisen-Chrom-Aluminium-Yttrium-Legierungen, sowie eine Strömungsmaschine mit einer derartigen Komponente.
摘要翻译：公开了一种用于流机热气传导部件，与锻造作为结构材料和选自铁 - 铬 - 铝 - 钇合金的热气体侧衬，以及具有这种组件的流体机械用镍基。

4. 发明申请

WO2012163991A1 VERFAHREN ZUM AUFBRINGEN EINER SCHUTZSCHICHT, MIT EINER SCHUTZSCHICHT BESCHICHTETES BAUTEIL UND GASTURBINE MIT EINEM SOLCHEN BAUTEIL 审中-公开
标题翻译：法将保护层施加保护涂层涂布组件和燃气轮机这样的一个组成部分
公开(公告)号：WO2012163991A1
公开(公告)日：2012-12-06
申请号：PCT/EP2012/060195
申请日：2012-05-31
申请人： MAN DIESEL & TURBO SE , CZECH, Norbert , CHANDRA, Sharad , HERZOG, Roland
发明人： CZECH, Norbert , CHANDRA, Sharad , HERZOG, Roland
IPC分类号： C23C4/02 , C23C4/18 , C23C10/02 , C23C10/60
CPC分类号： F01D5/288 , C23C4/02 , C23C4/10 , C23C4/134 , C23C4/18 , C23C10/02 , C23C10/60 , Y10T428/12611
摘要： Verfahren zum Aufbringen einer Schutzschicht, mit einer Schutzschicht beschichtetes Bauteil und Gasturbine mit einem solchen Bauteil, wobei bei dem Verfahren auf ein Basismetall (11) eine Haftschicht (12) auf MCrAI Y-Basis aufgebracht wird, die Haftschicht (12) durch Überalitierung mit einer AI-Diffusionschicht (14) überzogen wird» die AI-Diffusionsschicht (14) einer Abrasivbehandlung unterzogen wird, so dass eine äußere Aufbauschicht (14.2) der AI-Diffusionschicht (14) entfernt wird, und auf die verbleibende Al-Diffusionschicht (14) eine keramische Wärmedämmschicht (13) aus durch Yttriumoxid teilstabilisiertem Zirkoniumoxid aufgebracht wird, so dass eine gegen Hochtemperaturkorrosion und Hochtemperaturerosion beständige Schutzschicht erzeugt wird. Gemäß der Erfindung soll das Verfahren eine gute Thermoermüdungsbeständigkeit der Schutzschicht erzielen, aber dennoch auf einfache Weise durchführbar sein. Dies wird u.a. dadurch erreicht, dass die keramische Wärmedämmschicht (13) durch atmosphärisches Plasmaspritzen auf die verbleibende Al-Diffusionschicht (14) aufgebracht wird.
摘要翻译：在这个过程中具有保护层涂敷的部件和具有这种成分组成的气体涡轮机将保护层施加到碱性金属（11）（12）一种方法，将粘合剂层施加到MCrAI Y型为主，所述粘合剂层（12）由Überalitierung用 AI-扩散层（14）被涂覆“的Al扩散层（14）进行研磨作用，使得外部结构层（14.2）被移除时，Al扩散层（14），并且剩余的Al扩散层（14）一个陶瓷热障涂层通过氧化钇部分稳定的氧化锆（13）施加的，从而使对高温腐蚀和高温耐侵蚀性层稳定被产生。根据本发明，该方法是实现保护层的良好的耐热疲劳性，但仍然以简单的方式是可行的。这将除其他外，实现，即，在陶瓷热障涂层（13）通过大气等离子喷涂剩余Al扩散层（14）上施加。

5. 发明申请

WO2011057243A2 ADMINISTRATION OF PLANT EXPRESSED ORAL TOLERANCE AGENTS 审中-公开
标题翻译：植物表达口服剂的管理
公开(公告)号：WO2011057243A2
公开(公告)日：2011-05-12
申请号：PCT/US2010/055978
申请日：2010-11-09
申请人： UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. , UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. , DANIELL, Henry , HERZOG, Roland, W.
发明人： DANIELL, Henry , HERZOG, Roland, W.
IPC分类号： A61K38/56 , A61K48/00 , A61K38/16 , A61P3/00 , A61P9/10 , A61P43/00
CPC分类号： A61K39/0008 , A61K38/4846 , C07K2319/55 , C12N9/644 , C12N15/8214 , C12N15/8257 , C12Y304/21022
摘要： Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine hemophilia B as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor IX (F. IX) expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated mice when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures to intravenous F. IX protein. While only 20-25% of control animals survived after 6-8 F. IX doses, 90-95% of tolerized mice survived 12 injections without signs of allergy or anaphylaxis. This high-responder strain of hemophilia B mice represents the first hemophilic animal model to study anaphylactic reactions. The plant material was effective over a range of oral antigen doses (equivalent to 5-80 μg recombinant F.IX/kg), and controlled inhibitor formation and anaphylaxis long-term, up to 7 months. Oral antigen administration caused a deviant immune response that suppressed formation of IgE and inhibitory antibodies. This cost-effective and efficient approach to oral delivery of protein antigens to the gut should be applicable to several genetic diseases that are prone to pathogenic antibody responses during treatment.
摘要翻译：血友病或其他遗传性蛋白质缺陷患者的蛋白质替代疗法通常与致病性抗体应答相复杂，包括中和治疗性蛋白质的抗体或易形成IgE的可能危及生命的过敏反应。使用鼠血友病B作为模型，我们制定了针对这种非侵入性应答的预防性方案，其不包括患者细胞的免疫抑制或遗传操作。在植物细胞中生物包被的叶绿体中表达的凝血因子IX（F-IX）的口服递送有效地阻止蛋白质替代疗法中抑制性抗体的形成。与对照组相比，抑制剂滴度在治疗的小鼠中大部分是不可检测的并且高达100倍。此外，这种治疗方法消除了静脉注射F. IX蛋白4至6次后发生的致命性过敏反应。在6-8F IX剂量后，只有20-25％的对照动物存活，90-95％的耐受小鼠在12次注射后存活，没有过敏症状或过敏症状。这种高反应性的血友病B小鼠品系代表了研究过敏反应的第一个血友病动物模型。植物材料在一系列口服抗原剂量（相当于5-80μg重组体F.IX / kg）内是有效的，并且长期控制的抑制剂形成和过敏反应长达7个月。口服抗原施用引起异常免疫应答，其抑制IgE和抑制性抗体的形成。这种将蛋白质抗原口服递送至肠道的经济有效的方法应该适用于在治疗过程中易发生致病性抗体应答的几种遗传疾病。

6. 发明申请

WO2010139762A1 A MEDICAL CLEANING KIT 审中-公开
标题翻译：医疗清洁工具包
公开(公告)号：WO2010139762A1
公开(公告)日：2010-12-09
申请号：PCT/EP2010/057786
申请日：2010-06-03
申请人： STRAUMANN HOLDING AG , FEHR, Daniel , HERZOG, Roland , LYNGSTADAAS, S. Petter , WOHLFAHRT, Johan, Caspar
发明人： FEHR, Daniel , HERZOG, Roland , LYNGSTADAAS, S. Petter , WOHLFAHRT, Johan, Caspar
IPC分类号： A61C19/06 , A61C5/02
CPC分类号： A61C19/063 , A46B3/18 , A46D1/00 , A46D1/0207 , A61C3/005 , A61C5/40 , A61C8/00
摘要： The present invention relates to the field of cleaning and/or conditioning of biological and dental implant surfaces. More particularly, the invention relates to a kit comprising a) a cleaning device said cleaning device (1) comprising: an elongated base member (2) formed of at least two wires (3) being twisted with each other, and a plurality of bristles (4) fixed between said twisted wires (3) and extending away from said twisted wires (3), whereby said bristles (4) are positioned in a cleaning section (5) at a first end (6) of said base member (2) wherein said bristles (4) consist of titanium or a titanium alloy; and b) a container comprising a composition comprising ethylene diaminotetraacetic acid (EDTA). The kit may be used for the cleaning and/or debridement and/or conditioning of a biological or dental implant surface in order to e.g. improve implant attachment and facilitate wound healing.
摘要翻译：本发明涉及生物和牙科植入物表面的清洁和/或调理领域。更具体地，本发明涉及一种包括a）清洁装置的清洁装置，所述清洁装置包括：由至少两根彼此扭曲的线（3）形成的细长基部构件（2），以及多个刷毛（4）固定在所述绞合线（3）之间并远离所述绞合线（3）延伸，由此所述刷毛（4）位于所述基底构件（2）的第一端（6）处的清洁部分（5）），其中所述刷毛（4）由钛或钛合金构成; 和b）包含包含乙二胺四乙酸（EDTA）的组合物的容器。该试剂盒可用于生物或牙科植入物表面的清洁和/或清创和/或调理，以便例如。改善植入物的附着和促进伤口愈合。

7. 发明申请

WO0191647A8 DEVICE FOR POSITIONING A SURGICAL INSTRUMENT 审中-公开
标题翻译：设备定位的手术器械
公开(公告)号：WO0191647A8
公开(公告)日：2002-02-21
申请号：PCT/CH0000307
申请日：2000-05-31
申请人： STRATEC MEDICAL AG , ZIRNGIBL NICOLAS , MATHYS STEFAN , HERZOG ROLAND , UHRI PATRICK
发明人： ZIRNGIBL NICOLAS , MATHYS STEFAN , HERZOG ROLAND , UHRI PATRICK
IPC分类号： A61B17/15 , A61B34/20 , A61B19/00
CPC分类号： A61B17/154 , A61B17/155 , A61B17/157 , A61B34/20 , A61B2034/2055
摘要： The invention relates to a device for positioning and/or guiding surgical instruments. Said device comprises: A) a rod-shaped longitudinal support (2) with a longitudinal axis (3); B) two transversal supports (5), which are transversal to the longitudinal axis (3), which each have a rear end (34) and a front end (35), and which, on the front ends (35), can be fixed to one of two respective bones or to a supporting frame; C) two blocks (4; 14), which are detachably fixed to the longitudinal support (2), which can be displaced thereon parallel to the longitudinal axis (3), and which are provided for joining the rear ends (34) of the transversal supports (5) to the longitudinal support (2), and; D) a slide (36), which can be axially displaced and stopped on the longitudinal support (2) with regard to the longitudinal axis (3), whereby: D) each block (4; 14) comprises a detachably lockable first joint (8), by means of which the respective transversal support (5) can be displaced relative to the longitudinal support (2) around at least two axes that are perpendicular to one another, and; (F) each transversal support (5) comprises a detachably lockable second joint (33).
摘要翻译：一种用于定位和/或引导手术器械，其中A）装置的纵向轴线（3），其具有棒状纵向构件（2）; B）被布置在两个横向的纵向轴线（3）的横构件（5），其具有各自的后端（34）和一个前端（35）和（在前面在一个分别两块骨或到支撑帧结束35）是可固定 ; C）2（在纵向梁2）平行于所述纵向轴线（3）可滑动和可释放地固定爪（4;所述横向支承件（5）的所述纵向构件14）（用于连接后端34）（2）; 和D）一种（侧构件上2）相对于所述纵向轴线（3）轴向移动的和可锁定的滑架（36），E）各颚板（4; 14）包括可释放地锁定，第一接头（8），通过该相应的通过相对于每个横向构件的纵向载体（2）是可移动的，和F）的至少两个相互垂直的轴线横向构件（5）（5）包括一个可释放地锁定，第二铰链（33）。

8. 发明申请

WO1994019052A1 TROCAR SLEEVE FOR RECEIVING A SURGERY INSTRUMENT 审中-公开
标题翻译：套管用于接收外科器械
公开(公告)号：WO1994019052A1
公开(公告)日：1994-09-01
申请号：PCT/EP1994000409
申请日：1994-02-12
申请人： AESCULAP AG , DÖTZKIRCHNER, Volker , HERZOG, Roland
发明人： AESCULAP AG
IPC分类号： A61M39/00
CPC分类号： A61B17/3498 , A61M39/06 , A61M2039/0626 , A61M2039/0686
摘要： A trocar sleeve (1) for receiving a surgery instrument has at least one flap (13) which forms a valve body. The flap (13) may be swivelled by the inserted surgery instrument to an open position and when the instrument is withdrawn, it swivels against the insertion direction of the instrument to a closed position in which the inner space of the trocar sleeve is closed. In order to improve the mechanical design of such a trocar sleeve and to achieve an improved sealing effect, the flap is made of a flexible elastomeric material, is held at one end of the trocar sleeve in a plane transverse to the longitudinal axis of the trocar and when it is in its closed position it rests on a step (9) of the inner space of the trocar sleeve so that the whole cross-section of the trocar sleeve inner space surrounded by the step is covered by the flap(s).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式